There's a single-drug pharmaceutical company that holds a dominant position in the US irritable bowel market, generates gross margins of over 91%, and is run by just 253 employees thanks to an elegant 50/50 profit-sharing model with one of the world's largest pharmaceutical giants. It reported Q1 2026 revenues 97% higher than a year ago and significantly beat analyst expectations - and yet the stock is down 13.6%.
Why? Because a few weeks before the results, the FDA rejected the company's second product, and investors began to do the math: patent protection on a key drug expires in 2029, when the first generics enter the market. So the company has a three-year window of peak revenue with adj. EBITDA of over $300 million per year with a market capitalization of just $634 million - and has engaged Goldman Sachs to look for strategic alternatives. Is this a value trap or contrarian opportunity of the decade?
Top points of analysis
The company reported Q1 2026 revenue of $106.5M (+159% YoY)…